Filtered By:
Drug: Dexamethasone
Procedure: Kidney Transplant
This page shows you your search results in order of date.
Order by Relevance | Date
Total 59 results found since Jan 2013.
A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee
Int J Hematol. 2023 Jul 29. doi: 10.1007/s12185-023-03647-2. Online ahead of print.ABSTRACTWe retrospectively gathered data of 21 patients (13 male and 8 female; median age 65 years) diagnosed with immunoglobulin M (IgM)-related light-chain (AL) amyloidosis in Japan to investigate characteristics of IgM-AL amyloidosis and its optimal treatment strategy. Median IgM and difference free light chain (FLC) at diagnosis were 1257 mg/dl and 34.3 mg/l, respectively. Organ involvement was observed in the heart in 7 patients (33%), kidneys in 15 (71%), and lymph nodes in 5 (24%). Initial treatments were melphalan/dexamethasone in 7 ...
Source: International Journal of Hematology - July 29, 2023 Category: Hematology Authors: Shin-Ichi Fuchida Mizuki Ogura Tadao Ishida Hiroyuki Hata Hiroshi Handa Nagaaki Katoh Chiaki Nakaseko Kazutaka Sunami Yuta Katayama Hironobu Nobata Kazuiku Oshiro Shinsuke Iida Yoshiki Sekijima Hironobu Naiki Chihiro Shimazaki Source Type: research
Renal failure in multiple myeloma: Specific management issues
Bull Cancer. 2023 Feb 7:S0007-4551(23)00042-5. doi: 10.1016/j.bulcan.2022.12.015. Online ahead of print.ABSTRACTRenal impairment is common during multiple myeloma and persistent reduction in kidney function strongly affects prognosis. Cast nephropathy, by monoclonal free light chains precipitation with uromodulin in renal tubules, is the main cause of acute kidney injury in multiple myeloma. Kidney biopsy, although not necessary for diagnosis, allows assessment of renal prognosis according to the extent of cast formation, tubular atrophy and interstitial fibrosis. Prevention and early diagnosis of acute kidney injury are e...
Source: Bulletin du Cancer - February 9, 2023 Category: Cancer & Oncology Authors: M élanie Try St éphanie Harel Source Type: research
What is The Best Choice in Steroid-Dependent Nephrotic Syndrome: Mycophenolate Mofetil Plus Dexamethasone or Cyclosporine A
In this study, we aimed to determine the efficiency, safety, and long-term results of MMF/DEX in patients with SDNS in comparison with cyclosporine A (CsA) in a retrospective single-center trial. Between January 2009 and December 2015, 54 SDNS patients were treated with either MMF/DEX (n = 29) or CsA (n = 25). Relapse rates, relapse-free time, cumulative exposure to corticosteroids, proteinuria, and estimated glomerular filtration rate (eGFR) were retrospectively evaluated at 0, 3, 6, 12, 24, and 36 months after the initiation of treatment. The mean cumulative exposure to corticosteroids for the MMF/DEX and CsA groups was ...
Source: Saudi Journal of Kidney Diseases and Transplantation - March 1, 2022 Category: Urology & Nephrology Authors: Se çil Conkar Tunçay Sevgi Mir G ülden Hakverdi Source Type: research
